沉默的负担:识别和管理光学神经炎的隐形症状
Lorena Lorefice1, Antonio Carotenuto2, Giuseppe Fenu3
1Multiple Sclerosis Center, ASL Cagliari, Binaghi Hospital, Cagliari, Italy lorena.lorefice@hotmail.it.
Journal of neurology, neurosurgery, and psychiatry
|June 12, 2025
概括
水素-4阳性神经脊髓炎光学谱系障碍 (AQP4+NMOSD) 通常会导致诸如疲劳和疼痛之类的看不见的症状. 改善对这些被忽视的症状的评估对于更好的AQP4+NMOSD管理和治疗至关重要.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 神经炎症是一种神经炎症.
背景情况:
- 水素4阳性神经脊髓炎光学谱系障碍 (AQP4+NMOSD) 是一种自身免疫性天体细胞变异症.
- 临床表现通常包括视觉,运动和感官缺陷.
- 看不见的症状,如疲劳,疼痛和神经精神问题显著影响患者的生活质量.
研究的目的:
- 系统地审查AQP4+NMOSD中被忽视的症状的文献.
- 探索疲劳,疼痛,神经精神症状和膀/肠道功能障碍的流行,评估和管理.
- 突出需要改善这些症状的检测和监测.
主要方法:
- 使用PubMed进行系统的文献综述.
- 关键词包括疲劳,疼痛,膀/肠道功能障碍,神经精神症状和AQP4+NMOSD.
- 分析重点是流行,评估和管理策略.
主要成果:
- 在AQP4+NMOSD患者中,经常会出现隐形症状.
- 尽管这些症状有很大的影响,但这些症状往往被忽视.
- 目前对这些症状的评估和管理策略需要加强.
结论:
- 在AQP4+NMOSD中,急需改进对隐形症状的检测和监测.
- 加强评估对于开发向治疗和了解疾病活动至关重要.
- 优化治疗策略需要解决AQP4+NMOSD症状的全部范围.
更多相关视频
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
11.4K
08:05Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
Published on: March 1, 2017
9.2K
相关概念视频
01:15Myasthenia Gravis: Diagnostic Tests
699
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
699
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K